CD274 and colorectal carcinoma: While T cell-centric immunotherapies, particularly PD-1/PD-L1 inhibitors, have achieved remarkable progress in microsatellite instability-high (MSI-H) CRC, their clinical efficacy remains limited in microsatellite stable (MSS) subtypes that account for 85% of CRC cases (4).